McGill University, Canada.
McGill University Health Center, Canada; Ingram School of Nursing, Canada.
Clin Nutr ESPEN. 2022 Jun;49:289-294. doi: 10.1016/j.clnesp.2022.03.036. Epub 2022 Mar 31.
The SMOFlipid is a composite emulsion that has showed benefits, but limited data is available on children receiving prolonged parenteral nutrition (PN). This study aimed to compare conjugated bilirubin (CB) levels at the end of ILE administration in this population.
Medical charts of all infants treated with Intralipid (Jan 2012-Sep 2013) or SMOFlipid (Oct 2013-Dec 2016) were reviewed. Only infants that received PN for ≥28 consecutive days were included. Laboratory data were extracted from the closest day of initiation and discontinuation of the ILE (±7 days). For the primary objective, an analysis of covariance was employed, adjusting for initial CB values and total days of ILE administration. CB values were log-transformed to normalize distribution. Statistical tests were two-sided and performed at the significance level <0.05.
A total of 150 infants were included: 72 used Intralipid for 82 times and 88 received SMOFlipid in 92 occasions. The incidence of cholestasis was 20% (Intralipid) and 4.5% (SMOFlipid). Infants treated with SMOFlipid had significantly lower CB levels at the end of ILE administration with geometric mean ratio between groups of 1.7 (95% CI:1.0, 2.8; p < 0.05).
In a large and heterogenous group of infants receiving PN for ≥28 consecutive days the final levels of CB were significantly lower with SMOFlipid when compared to Intralipid suggesting a protective role of this type of ILE in this high-risk population.
SMOFlipid is an emulsion that has showed benefits, but limited data is available on children receiving prolonged parenteral nutrition (PN). This study compared conjugated bilirubin (CB) levels at the end of ILE administration in infants that received PN for ≥28 consecutive days with either SMOFlipid or Intralipid. In a large number of patients with several gastrointestinal diseases lower CB levels were observed with the use of SMOFlipid with geometric mean ratio between groups of 1.7 (95% CI:1.0, 2.8; p < 0.05). Our results demonstrate a protective role of this type of ILE in this high-risk population.
SMOFlipid 是一种复合乳剂，已显示出益处，但有关接受长期肠外营养（PN）的儿童的数据有限。本研究旨在比较该人群中结束 ILE 治疗时结合胆红素（CB）的水平。
回顾了所有接受 Intralipid（2012 年 1 月至 2013 年 9 月）或 SMOFlipid（2013 年 10 月至 2016 年 12 月）治疗的婴儿的病历。仅纳入接受 PN 治疗≥28 天的婴儿。从 ILE 开始和停止的最近一天（±7 天）提取实验室数据。对于主要目标，采用协方差分析，调整初始 CB 值和 ILE 给药的总天数。将 CB 值进行对数转换以使其分布正常化。统计检验为双侧，显著性水平<0.05。
共纳入 150 名婴儿：72 名婴儿使用 Intralipid 进行 82 次治疗，88 名婴儿接受 SMOFlipid 进行 92 次治疗。胆泥淤积的发生率为 20%（Intralipid）和 4.5%（SMOFlipid）。与 Intralipid 相比，接受 SMOFlipid 治疗的婴儿在 ILE 治疗结束时的 CB 水平明显较低，两组之间的几何均数比为 1.7（95%CI：1.0，2.8；p<0.05）。
在接受≥28 天连续 PN 治疗的大型异质婴儿组中，与 Intralipid 相比，SMOFlipid 治疗的终末 CB 水平明显较低，提示这种 ILE 在这种高危人群中具有保护作用。
SMOFlipid 是一种已显示出益处的乳剂，但有关接受长期肠外营养（PN）的儿童的数据有限。本研究比较了接受 PN 治疗≥28 天的婴儿使用 SMOFlipid 或 Intralipid 治疗时 ILE 治疗结束时结合胆红素（CB）的水平。在患有多种胃肠道疾病的大量患者中，使用 SMOFlipid 观察到 CB 水平降低，两组之间的几何均数比为 1.7（95%CI：1.0，2.8；p<0.05）。我们的结果表明，这种 ILE 在高危人群中具有保护作用。
